Since survivin, XIAP, TAB1 and TAK1 are involved in the anticancer effects of Sur-X, it can be inferred that Sur-X may have broader efficacy in cancer patients with high expression of survivin, XIAP, TAB1 and/or TAK1. The gene discussed is BIRC5; the disease is cancer.